Comparison of an LH-RH analogue (goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: Final survival results of an international multicentre randomized-trial

Chris J. Tyrrell, J. E. Altwein, F. Klippel, C. Jurincic-Winkler, E. Varenhorst, G. Lunglmayr, F. Boccardo, I. M. Holdaway, J. M. Haefliger, J. P. Jordaan

Research output: Contribution to journalArticle

Abstract

Objective: The aim of this study was to compare the effects of the nonsteroidal antiandrogen flutamide plus the LH-RH analogue goserelin acetate (combined androgen blockade [CAB]) with goserelin acetate alone in patients with advanced prostate cancer. The original analyses at 25 and 56 months of follow-up have been reported previously, and here we report the final survival analysis after 10 years of follow-up. Methods: 589 patients with advanced prostate cancer (55% with metastatic [M1] and 45% with locally advanced [M0] disease) were randomized to receive goserelin acetate 3.6 mg either alone or in combination with flutamide (250 mg three times daily). Results: A total of 583 patients were included in the analysis. There was a small, but nonsignificant, benefit for CAB compared with goserelin acetate alone in all patients with respect to survival (hazard ratio 0.88, 95% CI 0.73, 1.06). Subgroup analysis of M0 and M1 patients showed similar results (M0: hazard ratio 0.92, 95% CI 0.68, 1.25; M1: hazard ratio 0.85, 95% CI 0.66, 1.08). The treatment effect was not significantly different for M0 and M1 patients (p = 0.685). Conclusions: In this large randomized trial containing significant numbers of M0 patients, after 10 years there was a small but nonsignificant benefit for CAB over castration alone. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish
Pages (from-to)205-211
Number of pages7
JournalEuropean Urology
Volume37
Issue number2
Publication statusPublished - 2000

    Fingerprint

Keywords

  • Advanced prostate cancer survival
  • Combined androgen blockade
  • Flutamide
  • Goserelin acetate
  • Luteinizing hormone-releasing hormone analogue

ASJC Scopus subject areas

  • Urology

Cite this

Tyrrell, C. J., Altwein, J. E., Klippel, F., Jurincic-Winkler, C., Varenhorst, E., Lunglmayr, G., Boccardo, F., Holdaway, I. M., Haefliger, J. M., & Jordaan, J. P. (2000). Comparison of an LH-RH analogue (goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: Final survival results of an international multicentre randomized-trial. European Urology, 37(2), 205-211.